- HBV relapse is more common and severe, and tends to occur earlier, among patients discontinuing tenofovir disoproxil fumarate (TDF) vs entecavir (ETV).
Why this matters
- Patients should be closely monitored in the 6 months following TDF discontinuation.
- Retrospective-prospective study of patients with chronic HBV stopping ETV (n=342) or TDF (n=165) and followed for ≥6 months.
- 68.4% and 72.1% of ETV- and TDF-treated patients, respectively, were negative for HBV envelope antigen (HBeAg).
- Funding: Ministry of Science and Technology of the Republic of China, Chang Gung Memorial Hospital.
- Virologic relapse rates were higher and earlier after TDF vs ETV:
- HBeAg+: 3 months, 28.3% vs 5.6%; 6 months, 56.5% vs 13.0%; 2 years, 72.4% vs 41.3% (all P<.001>
- HBeAg–: 3 months, 20.2% vs 5.6%; 6 months, 45.4% vs 29.1% (both P<.001 years vs>
- HBeAg+: 6 months, 32.6% vs 5.6%; 2 years, 63.5% vs 33.0% (both P<.001>
- HBeAg–: 6 months, 27.0% vs 10.3% (P<.001 years vs>
- Observational design.